Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6736 to 6750 of 7707 results

  1. Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]

    Discontinued [GID-TA10324]

    Technology appraisal guidance
    Discontinued

  2. Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

    Discontinued [GID-TA10180]

    Technology appraisal guidance
    Discontinued

  3. Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy [ID1347]

    Discontinued [GID-TA10264]

    Technology appraisal guidance
    Discontinued

  4. Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

    Discontinued [GID-TA10570]

    Technology appraisal guidance
    Discontinued

  5. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued [GID-TAG479]

    Technology appraisal guidance
    Discontinued

  6. Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

    Discontinued [GID-TA10109]

    Technology appraisal guidance
    Discontinued

  7. Prostate cancer (hormone refractory) - atrasentan [ID390]

    Discontinued [GID-TAG379]

    Technology appraisal guidance
    Discontinued

  8. Enzalutamide for the treatment of hormone refractory prostate cancer TA316

    Discontinued [GID-TA10267]

    Technology appraisal guidance
    Discontinued

  9. Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610]

    Discontinued [GID-TA10499]

    Technology appraisal guidance
    Discontinued

  10. Everolimus with exemestane for treating HER2-negative hormone-receptor-positive breast cancer after endocrine therapy [ID965]

    Discontinued [GID-TA10028]

    Technology appraisal guidance
    Discontinued

  11. Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732]

    Discontinued [GID-TAG482]

    Technology appraisal guidance
    Discontinued

  12. Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

    Discontinued [GID-TA10254]

    Technology appraisal guidance
    Discontinued

  13. Hernia

    Discontinued [GID-CGWAVE0771]

    NICE guideline
    Discontinued

  14. Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

    Discontinued [GID-TA10234]

    Technology appraisal guidance
    Discontinued

  15. Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]

    Discontinued [GID-TA10427]

    Technology appraisal guidance
    Discontinued